Images List Premium Download Classic

Steatohepatitis

Steatohepatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Cenicriviroc for the treatment of fibrosis
Tobira Therapeutics ,inc.
August 24, 2017 - N°20170239262

The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvate thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (...
Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
Nusirt Sciences, Inc.
August 24, 2017 - N°20170239253

Methods useful for sustaining a reduction of non-alcoholic steatohepatitis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or pde5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for ...
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting ...
Yale University
August 17, 2017 - N°20170232027

The invention includes a method of preventing or treating a toxic liver disease or disorder, such as but not limited to non-alcoholic steatohepatitis (nash), liver injury associated with or caused by alcohol consumption in a mammal afflicted with nash, alcoholic hepatitis, drug induced liver injury, primary sclerosing cholangitis, viral hepatitis, liver fibrosis, liver cirrhosis, and other toxic liver conditions, in ...
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical compositions of berberine with epa and dha, and methods thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
May 18, 2017 - N°20170135995

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, ...
Tiopronin prodrugs, pharmaceutical compositions thereof, and methods of use
Shenzhen Hightide Biopharmaceutical, Ltd.
May 11, 2017 - N°20170129867

Tiopronin prodrugs, pharmaceutical compositions comprising the tiopronin prodrugs, and methods of using tiopronin prodrugs and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, parkinson's disease, and huntington's disease.
Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of ...
Industry-academic Cooperation Foundation, Yonsei University
May 04, 2017 - N°20170121380

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 or a fragment thereof with a human antibody fc region. Also provided are health functional foods containing a dlk1-fc ...
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Thyromimetics for the treatment of fatty liver diseases
Metabasis Therapeutics, Inc.
April 27, 2017 - N°20170112864

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
Hadasit Medical Research Services And Development Ltd.
April 20, 2017 - N°20170105996

Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
Uses of mito-ob transgenic mice
University Of Manitoba
March 30, 2017 - N°20170089888

The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes. It has been discovered that these mice also spontaneously develop nonalcoholic steatohepatitis (nash) and hepatocarcinogenesis over time. Also described is a mutant mito-ob mouse that develops lymphadenopathy and histiocytosis.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
March 30, 2017 - N°20170087127

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Novel compounds as diacylglycerol acyltransferase inhibitors
Glaxosmithkline Llc
March 23, 2017 - N°20170081342

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of ...
Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use
Glaxosmithkline Llc
March 23, 2017 - N°20170081280

Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, n-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, n-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial ...
Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use
Glaxosmithkline Llc
March 23, 2017 - N°20170081279

Cysteamine prodrugs, pharmaceutical compositions comprising the cysteamine prodrugs, and methods of using cysteamine prodrugs and pharmaceutical compositions thereof for treating eye, kidney, liver, metabolic, and neurological disorders such as cystinosis, cystinuria, non-alcoholic steatohepatitis, batten disease, leigh syndrome, and huntington's disease.
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated ...
Vanderbilt University
February 16, 2017 - N°20170042964

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject. Compositions and methods including a nuclear transport modifier may ...
Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
Shenzhen Hightide Biopharmaceutical, Ltd.
February 09, 2017 - N°20170037043

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their ...
Compositions and methods for treating non-alcoholic steatohepatitis
Mochida Pharmaceutical Co., Ltd.
January 12, 2017 - N°20170007566

Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatis (nash).
Systems, devices and methods for performing medical procedures in the intestine
Fractyl Laboratories, Inc.
January 12, 2017 - N°20170007310

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element. The catheter is introduced ...
Glucagon and glp-1 co-agonist compounds
Eli Lilly And Company
December 22, 2016 - N°20160368960

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).
Lysosomal acid lipase therapy for nafld and related diseases
Children's Hospital Medical Center
December 22, 2016 - N°20160367645

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for ...
Animal model of nash-induced hepatocellular carcinoma and methods for developing specific therapeutics
The Regents Of The University Of California
December 15, 2016 - N°20160360735

The invention provides a non-human animal model for non-alcoholic steatohepatitis (nash)-induced heptocellular carcinoma, methods of screening for agents for treating heptocellular carcinoma, methods of screening for targets useful in suppressing nash progression to heptocellular carcinoma, methods of treating heptocellular carcinoma, and compositions for treating the same.
Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof
The Regents Of The University Of California
December 08, 2016 - N°20160354387

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelithiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced ...
Loading